Compare
BriaCell Therapeutics Corp. vs Immunic, Inc. vs Rein Therapeutics, Inc. vs Kiora Pharmaceuticals Inc
| Latest fiscal year | BriaCell Therapeutics Corp. BCTX | Immunic, Inc. IMUX | Rein Therapeutics, Inc. RNTX | Kiora Pharmaceuticals Inc KPRX |
|---|---|---|---|---|
| Year ended | 2026-07-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | $0 |
| Revenue growth (YoY) | n/a | n/a | n/a | -100.0% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$34.90M | -$97.17M | -$49.87M | -$10.84M |
| EPS (Diluted) | -$6.97 | -$0.62 | -$1.96 | -$2.64 |
| Operating cash flow | -$28.65M | -$85.81M | -$19.36M | -$9.96M |
| Free cash flow | -$28.78M | -$85.97M | n/a | -$10.07M |
| Cash & equivalents | $9.85M | $15.48M | $3.21M | $8.70M |
| Total assets | $23.58M | $24.05M | $24.16M | $24.25M |
| Total liabilities | n/a | $30.73M | $7.24M | $8.13M |
| Shareholders' equity | $15.56M | -$6.67M | $16.92M | $16.13M |
| Return on year-end equity | -224.3% | n/a | -294.8% | -67.2% |
| Shares outstanding | 8.71M | 90.15M | 27.55M | 3.76M |
Revenue, most recent five fiscal years
| Fiscal year | BriaCell Therapeutics Corp. | Immunic, Inc. | Rein Therapeutics, Inc. | Kiora Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | n/a | n/a | $0 Ended 2025-12-31 | $0 Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $0 Ended 2024-12-31 | $16.02M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $0 Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $0 Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $0 Ended 2021-12-31 | $0 Ended 2021-12-31 |